Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian treatment guidelines

References

[1] Cabibbo G,Borzio M.Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice treatment guidelines of the Italian association for the study of the liver (AISF), Italian association of medical oncology (AIOM), Italian association of hepato-bilio-pancreatic surgery (AICEP), Italian association of hospital gastroenterologists (AIGO), Italian association of radiology and clinical oncology (AIRO), Italian society of pathological anatomy and diagnostic cytology (SIAPeC-IAP), Italian society of surgery (SIC), Italian society of gastroenterology (SIGE), Italian society of medical and interventional radiology (SIRM), Italian organ transplant society (SITO), and association of patients with hepatitis and liver disease (EpaC) - part II - non-surgical treatments.Dig Liver Dis2024;56:394-405

[2] Mancini S,Zamagni F.Trends in liver cancer incidence and survival in Italy by histologic type, 2003-2017.Cancers2022;14:6162 PMCID:PMC9777051

[3] Farinati F,Spolverato G.ITALI.CA study group. Development and validation of a new prognostic system for patients with hepatocellular carcinoma.PLoS Med2016;13:e1002006 PMCID:PMC4846017

[4] Borzio M,Rossini A.External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study.Hepatology2018;67:2215-25

[5] Shin SW,Kim SW,Kim YH.Liver resection versus local ablation therapies for hepatocellular carcinoma within the Milan criteria: a systematic review and meta-analysis.Ann Surg2021;273:656-66

[6] Mazzaferro V,Doci R.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med1996;334:693-9

[7] Murali AR,Phillips KT.Locoregional therapy with curative intent versus primary liver transplant for hepatocellular carcinoma: systematic review and meta-analysis.Transplantation2017;101:e249-57

[8] Ryu T,Wada Y,Sasaki S.Hepatic resection versus operative microwave ablation for single hepatocellular carcinoma ≤ 5 cm: a propensity score-matched analysis.Surgery2019;166:254-62

[9] Chu HH,Yoon HK.Chemoembolization combined with radiofrequency ablation for medium-sized hepatocellular carcinoma: a propensity-score analysis.J Vasc Interv Radiol2019;30:1533-43

[10] Lin CW,Lo GH.Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.BMC Gastroenterol2020;20:99 PMCID:PMC7147026

[11] Lewis S,Barry A,Mohamad I.Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity.JHEP Rep2022;4:100498 PMCID:PMC9289870

[12] Li C,Yan LN.Liver resection versus liver resection plus TACE for patients with hepatocellular carcinoma beyond Milan criteria.J Surg Res2017;209:8-16

[13] Su TS,Zhou Y.Stereotactic body radiation therapy vs. transarterial chemoembolization in inoperable barcelona clinic liver cancer stage a hepatocellular carcinoma: a retrospective, propensity-matched analysis.Front Oncol2020;10:347 PMCID:PMC7105822

[14] Hara K,Tsurugai Y.Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis.Hepatology2019;69:2533-45

[15] Sapir E,Schipper MJ.Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma.Int J Radiat Oncol Biol Phys2018;100:122-30 PMCID:PMC5818982

[16] Salem R,Kim E.Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study.Hepatology2021;74:2342-52 PMCID:PMC8596669

[17] Facciuto ME,Rocca JP.Surgical treatment of hepatocellular carcinoma beyond Milan criteria. results of liver resection, salvage transplantation, and primary liver transplantation.Ann Surg Oncol2008;15:1383-91

[18] Lai Q,Halazun K.Identification of an upper limit of tumor burden for downstaging in candidates with hepatocellular cancer waiting for liver transplantation: a west-east collaborative effort.Cancers (Basel)2020;12:452 PMCID:PMC7072306

[19] Sposito C. Liver transplantation for hepatocellular carcinoma. In: Ettorre, G.M. (eds) Hepatocellular Carcinoma. Updates in Surgery. Springer, Cham; 2022. P. 155-162.

[20] Lu L,Wu Z.Hepatic resection versus transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a cohort study.Front Oncol2021;11:618937 PMCID:PMC8579001

[21] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.J Hepatol2022;76:681-93 PMCID:PMC8866082

[22] Hashmi IN,Wedd JP.A narrative review of supportive and end of life care considerations in advanced hepatocellular carcinoma.Ann Palliat Med2023;12:1260-74

[23] Soliman H,Jiang H.Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases.J Clin Oncol2013;31:3980-6

[24] Pinato DJ,Sharma R.A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI).Br J Cancer2012;106:1439-45 PMCID:PMC3326674

[25] Jeng LB,Teng CF.Prognostic significance of serum albumin level and albumin-based mono- and combination biomarkers in patients with hepatocellular carcinoma.Cancers2023;15:1005 PMCID:PMC9953807